AZD0486

Phase 3Small molecule

AstraZeneca

AZD0486 is one of 64 small molecule programs targeting Chronic Lymphocytic Leukaemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lymphocytic LeukaemiaRecruiting

B-Cell Acute Lymphoblastic Leukemia (b-ALL)Recruiting

ElderlyRecruiting

LymphomaRecruiting

Chronic Lymphocytic LeukaemiaPreclinical

Recruiting

B-Cell Acute Lymphoblastic Leukemia (b-ALL)Preclinical

Recruiting

ElderlyPhase 3

Recruiting

LymphomaPhase 1

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

AZD0486

AstraZeneca

Phase 3

1 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Lymphoma

NCT04594642

Q3 2028

PreclinicalRecruiting

B-Cell Acute Lymphoblastic Leukemia (b-ALL)

NCT06137118

Q2 2029

PreclinicalRecruiting

Chronic Lymphocytic Leukaemia

NCT06564038

Q3 2033

Phase 3Recruiting

Elderly

NCT07215585

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT04594642·317 enrolled

Elderly1 trial

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07215585·420 enrolled

Chronic Lymphocytic Leukaemia1 trial

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06564038·408 enrolled

B-cell Acute Lymphoblastic Leukemia (B-ALL)1 trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06137118·255 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AZD0486. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD0486 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD0486. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

AZD0486

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q2 2029

Q3 2033

Trials by Indication[1]

Lymphoma1 trial

Elderly1 trial

Chronic Lymphocytic Leukaemia1 trial

B-cell Acute Lymphoblastic Leukemia (B-ALL)1 trial

References

Drug Info

Quick Facts

Related News